The role of erythropoietin in the acute phase of trauma management: evidence today.

[1]  S. Voulgaris,et al.  The efficacy of erythropoietin on acute spinal cord injury. An experimental study on a rat model , 2009, Archives of Orthopaedic and Trauma Surgery.

[2]  N. Yazıhan,et al.  Erythropoietin improves oxidative stress following spinal cord trauma in rats. , 2008, Injury.

[3]  T. Scalea,et al.  Low-dose recombinant factor VIIa for trauma patients with coagulopathy. , 2008, Injury.

[4]  P. Barie,et al.  The contemporary approach to the care of Jehovah's witnesses. , 2008, The Journal of trauma.

[5]  Y. Robinson.  Evidence‐based management of anaemia in severely injured patients , 2008, Acta anaesthesiologica Scandinavica.

[6]  K. Shermock,et al.  Erythropoietic agents for anemia of critical illness. , 2008, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

[7]  M. Joyeux-faure.  Cellular Protection by Erythropoietin: New Therapeutic Implications? , 2007, Journal of Pharmacology and Experimental Therapeutics.

[8]  S. Flohe,et al.  Immunological reactions secondary to blood transfusion. , 2007, Injury.

[9]  C. Ellingsen,et al.  Epidemiology and Contemporary Patterns of Trauma Deaths: Changing Place, Similar Pace, Older Face , 2007, World Journal of Surgery.

[10]  T. Fabian,et al.  Efficacy and safety of epoetin alfa in critically ill patients. , 2007, The New England journal of medicine.

[11]  P. Cameron,et al.  Massive blood transfusion and trauma resuscitation. , 2007, Injury.

[12]  I. Civil.  Improved outcomes after polytrauma: do we know the reasons? , 2007, Injury.

[13]  Frederick P Rivara,et al.  International comparison of prehospital trauma care systems. , 2007, Injury.

[14]  M. Parr,et al.  The use of recombinant activated factor VII in trauma patients: Experience from the Australian and New Zealand haemostasis registry. , 2007, Injury.

[15]  J. Jahr,et al.  Blood substitutes as pharmacotherapies in clinical practice , 2007, Current opinion in anaesthesiology.

[16]  I. Mushahwar.  Verses, viruses, and the vulnerability of the blood supply in industrialized countries , 2007, Journal of medical virology.

[17]  A. Ganser,et al.  Hematopoietic growth factors in the treatment of acquired bone marrow failure states. , 2007, Seminars in hematology.

[18]  Hans Gombotz,et al.  Estimating the cost of blood: past, present, and future directions. , 2007, Best practice & research. Clinical anaesthesiology.

[19]  T. Chang,et al.  Polyhemoglobin-Fibrinogen: A Novel Oxygen Carrier with Platelet-Like Properties in a Hemodiluted Setting , 2007, Artificial cells, blood substitutes, and immobilization biotechnology.

[20]  R. Pirker.  Safety considerations for erythropoietin treatment in patients with cancer , 2007, Expert opinion on drug safety.

[21]  W. Mutschler,et al.  Massive blood transfusion and outcome in 1062 polytrauma patients: a prospective study based on the Trauma Registry of the German Trauma Society , 2007, Vox sanguinis.

[22]  A. Moonen,et al.  Peri-operative blood management in elective orthopaedic surgery. A critical review of the literature. , 2006, Injury.

[23]  L. McIntyre,et al.  Can we safely restrict transfusion in trauma patients? , 2006, Current opinion in critical care.

[24]  R. Winslow,et al.  A Multicenter Clinical Study of the Safety and Activity of Maleimide-Polyethylene Glycol–modified Hemoglobin (Hemospan®) in Patients Undergoing Major Orthopedic Surgery , 2006, Anesthesiology.

[25]  W. Ertel,et al.  Erythropoiesis in multiply injured patients. , 2006, The Journal of trauma.

[26]  M. Corwin,et al.  Efficacy of recombinant human erythropoietin in critically ill patients admitted to a long-term acute care facility: A randomized, double-blind, placebo-controlled trial* , 2006, Critical care medicine.

[27]  M. Yaqoob,et al.  Erythropoietin and acute renal failure. , 2006, Seminars in nephrology.

[28]  S. Bonovas,et al.  Auditing 655 fatalities with pelvic fractures by autopsy as a basis to evaluate trauma care. , 2006, Journal of the American College of Surgeons.

[29]  Luciana Andrea Digieri,et al.  The care of a child with multiple trauma and severe anemia who was a Jehovah's Witness , 2006, Hematology.

[30]  L. Napolitano.  Cumulative risks of early red blood cell transfusion. , 2006, The Journal of trauma.

[31]  J. Stubbs.  Alternatives to blood product transfusion in the critically ill: Erythropoietin , 2006, Critical care medicine.

[32]  D. Demetriades,et al.  Blood transfusion in critically injured patients: a prospective study. , 2006, Injury.

[33]  M. Bhandari,et al.  Issues in the planning and conduct of randomised trials. , 2006, Injury.

[34]  Mohit Bhandari,et al.  Evidence-based medicine: what it is and what it is not. , 2006, Injury.

[35]  A. Gettinger,et al.  Transfusion therapy in the intensive care unit , 2006, Current opinion in anaesthesiology.

[36]  K. Eckardt,et al.  Erythropoietin in the critically ill: what is the evidence? , 2005, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[37]  D. Spahn,et al.  Artificial O2 carriers: status in 2005. , 2005, Current pharmaceutical design.

[38]  J. A. García-Erce,et al.  Efectividad de distintas pautas de tratamiento de la anemia perioperatoria en pacientes ancianos con fractura de cadera , 2005 .

[39]  L. Goodnough.  Risks of blood transfusion. , 2005, Critical care medicine.

[40]  O. Gajic,et al.  Transfusion-related acute lung injury. , 2005, Mayo Clinic proceedings.

[41]  R. Margreiter,et al.  Unusual impalement injury in a Jehovah's Witness. , 2005, The Journal of thoracic and cardiovascular surgery.

[42]  Á. Martínez,et al.  Perioperative stimulation of erythropoiesis with intravenous iron and erythropoietin reduces transfusion requirements in patients with hip fracture. A prospective observational study , 2005, Vox sanguinis.

[43]  P. Pronovost,et al.  Number needed to treat and cost of recombinant human erythropoietin to avoid one transfusion-related adverse event in critically ill patients* , 2005, Critical care medicine.

[44]  P. Giannoudis,et al.  Damage control orthopaedics: evolving concepts in the treatment of patients who have sustained orthopaedic trauma. , 2005, Instructional course lectures.

[45]  R. Dodd.  Current Safety of the Blood Supply in the United States , 2004, International journal of hematology.

[46]  H. Ehrenreich,et al.  A novel role for an established player: anemia drug erythropoietin for the treatment of cerebral hypoxia/ischemia. , 2004, Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis.

[47]  M. Brines,et al.  Science review: Recombinant human erythropoietin in critical illness: a role beyond anemia? , 2004, Critical care.

[48]  R. MacLaren,et al.  Use of exogenous erythropoietin in critically ill patients , 2004, Journal of clinical pharmacy and therapeutics.

[49]  S. Shafi,et al.  Fluid resuscitation and blood replacement in patients with polytrauma. , 2004, Clinical orthopaedics and related research.

[50]  D. Henry.  The evolving role of epoetin alfa in cancer therapy. , 2004, The oncologist.

[51]  D. Pafilas,et al.  Blood saving protocol in elective total knee arthroplasty. , 2004, American journal of surgery.

[52]  A. Shander.  Surgery without blood , 2003, Critical care medicine.

[53]  L. Fleming,et al.  The risk of death for Jehovah's Witnesses after major trauma. , 2003, The Journal of trauma.

[54]  L. Goodnough,et al.  Bloodless medicine: clinical care without allogeneic blood transfusion , 2003, Transfusion.

[55]  S. Kleinman,et al.  Risks associated with transfusion of cellular blood components in Canada. , 2003, Transfusion medicine reviews.

[56]  J. Meding,et al.  Perioperative Blood Management Practices in Elective Orthopaedic Surgery , 2002, The Journal of the American Academy of Orthopaedic Surgeons.

[57]  J. Vincent,et al.  Anemia and blood transfusion in critically ill patients. , 2002, JAMA.

[58]  S. Stramer,et al.  Current prevalence and incidence of infectious disease markers and estimated window‐period risk in the American Red Cross blood donor population , 2002, Transfusion.

[59]  W. Shoemaker,et al.  Reliable variables in the exsanguinated patient which indicate damage control and predict outcome. , 2001, American journal of surgery.

[60]  A. Cerami,et al.  Beyond erythropoiesis: novel applications for recombinant human erythropoietin. , 2001, Seminars in hematology.

[61]  F. Brenneman,et al.  Advances in fluid resuscitation of hemorrhagic shock. , 2001, Canadian journal of surgery. Journal canadien de chirurgie.

[62]  I. Chin-Yee,et al.  The clinical consequences of the red cell storage lesion. , 2001, Transfusion medicine reviews.

[63]  G. Mullane,et al.  Treating severe anemia in a trauma patient who is a Jehovah's witness. , 2001, Critical care nurse.

[64]  M. Schein,et al.  Multiple organ failure. How valid is the "two hit" model? , 1999, Journal of accident & emergency medicine.

[65]  G. Wells,et al.  A multicenter, randomized, controlled clinical trial of transfusion requirements in critical care. Transfusion Requirements in Critical Care Investigators, Canadian Critical Care Trials Group. , 1999, The New England journal of medicine.

[66]  Lee,et al.  Economic analysis of erythropoietin use in orthopaedic surgery , 1999, Transfusion medicine.

[67]  A. Schmidt,et al.  Blood conservation in hip trauma. , 1998, Clinical orthopaedics and related research.

[68]  M. Ritter,et al.  Epoetin alfa. A bloodless approach for the treatment of perioperative anemia. , 1998, Clinical orthopaedics and related research.

[69]  Y. Beguin.  A Risk-Benefit Assessment of Epoetin in the Management of Anaemia Associated with Cancer , 1998, Drug safety.

[70]  E. Moore,et al.  The first randomized trial of human polymerized hemoglobin as a blood substitute in acute trauma and emergent surgery. , 1998, Journal of the American College of Surgeons.

[71]  A. Sauaia,et al.  Blood Transfusion: An Independent Risk Factor for Postinjury Multiple Organ Failure , 1997 .

[72]  D. Wisner,et al.  Jehovah's Witnesses: unique problems in a unique trauma population. , 1997, Journal of the American College of Surgeons.

[73]  M. Tryba.  Epoetin alfa plus autologous blood donation and normovolemic hemodilution in patients scheduled for orthopedic or vascular surgery. , 1996, Seminars in hematology.

[74]  M. Goldberg,et al.  Erythropoiesis, erythropoietin, and iron metabolism in elective surgery: preoperative strategies for avoiding allogeneic blood exposure. , 1995, American journal of surgery.

[75]  H. Klein,et al.  Allogeneic transfusion risks in the surgical patient. , 1995, American journal of surgery.

[76]  G. Timberlake,et al.  Severe anemia in the Jehovah's Witness: case report and discussion. , 1993, American journal of critical care : an official publication, American Association of Critical-Care Nurses.

[77]  M. Goldberg,et al.  Regulation of erythropoietin production. , 1993, Experimental hematology.

[78]  L. Goodnough,et al.  Blood Transfusions in Hip Fracture Patients: Implications for Blood Conservation Programs , 1993, Journal of orthopaedic trauma.

[79]  J. Lipman,et al.  Erythropoietin in a patient following multiple trauma , 1992, Anaesthesia.

[80]  R. G. Gaines Das,et al.  The International Standard for Recombinant DNA-derived Erythropoietin: collaborative study of four recombinant DNA-derived erythropoietins and two highly purified human urinary erythropoietins. , 1992, The Journal of endocrinology.

[81]  R. Marquet,et al.  Efficacy of recombinant erythropoietin for stimulating erythropoiesis after blood loss and surgery. An experimental study in rats. , 1992, The European journal of surgery = Acta chirurgica.

[82]  L. Nelson,et al.  Use of recombinant human erythropoietin (r-HuEPO) in a Jehovah's Witness refusing transfusion of blood products: case report. , 1990, The Journal of trauma.

[83]  R. Jim.  Use of erythropoietin in Jehovah's Witness patients. , 1990, Hawaii medical journal.

[84]  C. H. Lin,et al.  Cloning and expression of the human erythropoietin gene. , 1985, Proceedings of the National Academy of Sciences of the United States of America.

[85]  S. Stawicki,et al.  The concept of damage control: extending the paradigm to emergency general surgery. , 2008, Injury.

[86]  R. Winslow.  Red cell substitutes. , 2007, Seminars in hematology.

[87]  H. Corwin.  The role of erythropoietin therapy in the critically ill. , 2006, Transfusion medicine reviews.

[88]  N. Tejwani,et al.  Evolving trends in the care of polytrauma patients. , 2006, Injury.

[89]  Kevin B. Jones,et al.  Effects of recombinant hematopoietins on blood-loss anemia in mice. , 2005, The Iowa orthopaedic journal.

[90]  J. Dunne,et al.  Allogenic blood transfusion in the first 24 hours after trauma is associated with increased systemic inflammatory response syndrome (SIRS) and death. , 2004, Surgical infections.

[91]  M. Gassmann,et al.  Non-erythroid functions of erythropoietin. , 2003, Advances in experimental medicine and biology.

[92]  R. Ohls.  Human Recombinant Erythropoietin in the Prevention and Treatment of Anemia of Prematurity , 2002, Paediatric drugs.

[93]  Blajchman Ma.  Incidence and significance of the bacterial contamination of blood components. , 2002 .

[94]  D. Mears,et al.  Developments in blood management: the potential therapeutic role for epoetin alfa in orthopedic trauma. , 1999, Orthopedics.

[95]  L. Goodnough,et al.  Parenteral Iron and Recombinant Human Erythropoietin Therapy to Stimulate Erythropoiesis in Patients Undergoing Repair of Hip Fracture. , 1996, Hematology.

[96]  S. Ferraris,et al.  Limiting excessive postoperative blood transfusion after cardiac procedures. A review. , 1995, Texas Heart Institute journal.

[97]  Imre Horváth,et al.  2 – Critical review of the literature , 1984 .